Alnylam Pharmaceuticals, Inc. (0HD2.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 07:05PM BST
| Previous close | 264.85 |
| Open | 265.08 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 265.08 - 273.08 |
| 52-week range | 143.66 - 273.08 |
| Volume | |
| Avg. volume | 1,441 |
| Market cap | 31.371B |
| Beta (5Y monthly) | 0.38 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
RARE's Bone Disorder Drug Gets FDA's Breakthrough Therapy Tag
Ultragenyx announces that the FDA grants Breakthrough Therapy designation to its investigational osteogenesis imperfecta treatment candidate, setrusumab.
- Simply Wall St.
Alnylam Pharmaceuticals Insiders Sold US$5.0m Of Shares Suggesting Hesitancy
The fact that multiple Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) insiders offloaded a considerable amount of shares...
- Simply Wall St.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Is Expected To Breakeven In The Near Future
With the business potentially at an important milestone, we thought we'd take a closer look at Alnylam Pharmaceuticals...
© 2024 Yahoo. All rights reserved.